Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Genedrive ( (GB:GDR) ) is now available.
Genedrive reported interim results to 31 December 2025, highlighting increased revenue but a stable operating loss as it invests in commercial expansion for its CYP2C19 and MT-RNR1 pharmacogenetic tests in the UK and abroad. The company has secured access to key NHS pathways, including implementation guidance, the Dynamic Procurement System, and multiple pilot and rollout programmes across England, Scotland, Ireland and Saudi Arabia, underpinning its push to embed rapid genetic testing in routine stroke and neonatal care.
Operationally, the CYP2C19 ID Kit is in use at England’s largest hyper acute stroke unit and in Scottish “test of change” pilots, while a 12‑month study is expanding its use into acute coronary syndrome and international market access and a U.S. 510(k) route are being mapped. The MT-RNR1 ID Kit is deployed in 14 UK hospitals under the PALOH‑UK programme, is part of a phased national roll‑out in Scotland, has been implemented in Dublin’s Rotunda Hospital, and will be trialled in a Saudi national pilot, collectively building real‑world evidence to support wider adoption.
Financially, Genedrive completed a post‑period equity raise of about £4.9m net, converted a £0.5m shareholder loan to equity, and reported it is now debt free with £3.65m in cash at 27 March 2026, up from £0.4m at period end. Management says the strengthened balance sheet will fund FDA submissions, manufacturing scale‑up, usability improvements and international registrations, positioning the business to transition from early commercial activity to more scalable revenues despite near‑term NHS funding constraints.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £0.94 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Spark’s Take on GDR Stock
According to Spark, TipRanks’ AI Analyst, GDR is a Neutral.
The score is held back primarily by weak financial performance—large ongoing losses, sustained cash burn, and a shrinking equity base despite minimal debt. Technicals are moderately supportive with price above key moving averages and positive MACD, but elevated RSI signals near-term overheating risk. Valuation remains challenging due to negative earnings (negative P/E).
To see Spark’s full report on GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based, commercial-stage pharmacogenetic testing specialist focused on rapid, point-of-care diagnostics that guide safer and more effective drug prescriptions in emergency and acute care. Its CE-IVD approved and NICE-recommended Genedrive CYP2C19 and MT-RNR1 ID Kits are already in NHS clinical use, targeting stroke patients’ response to Clopidogrel and preventing antibiotic-induced hearing loss in newborns, respectively, with a strategy to scale UK-developed precision diagnostics and drive international adoption.
Average Trading Volume: 5,817,006
Technical Sentiment Signal: Sell
Current Market Cap: £15.65M
For detailed information about GDR stock, go to TipRanks’ Stock Analysis page.